Gastrointestinal Stromal Tumor

MONDO:0011719 Pathograph 4 gastrointestinal neoplasm

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors. GISTs are characterized by activating mutations in KIT (85%) or PDGFRA (10%) receptor tyrosine kinases, which drive constitutive kinase activation and tumor growth. The identification of these driver mutations revolutionized treatment, with imatinib demonstrating dramatic responses and establishing GIST as a paradigm for targeted therapy in solid tumors.

Ask OpenScientist

Ask a research question about Gastrointestinal Stromal Tumor. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
0
Inheritance
4
Pathophysiology
1
Histopathology
5
Phenotypes
4
Pathograph
2
Genes
4
Treatments
3
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
5
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
cancer solid tumor
ICD-O Morphology
Sarcoma
◆

Subtypes

3
KIT-mutant GIST
Approximately 85% of GISTs harbor activating mutations in KIT, most commonly in exon 11 (juxtamembrane domain) but also in exons 9, 13, and 17. Different mutations confer variable sensitivity to tyrosine kinase inhibitors.
PDGFRA-mutant GIST
Approximately 10% of GISTs harbor PDGFRA mutations, typically exon 18 D842V which is resistant to imatinib. These tumors often arise in the stomach and have an epithelioid morphology.
Wild-type GIST
Approximately 10-15% of GISTs lack KIT or PDGFRA mutations. This group includes SDH-deficient GISTs (pediatric/young adult), NF1-associated GISTs, and GISTs with BRAF, RAS, or receptor tyrosine kinase fusions.
⚙

Pathophysiology

4
KIT Receptor Tyrosine Kinase Activation
Gain-of-function mutations in KIT result in constitutive receptor dimerization and kinase activation without ligand (stem cell factor) binding. This drives downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell proliferation and survival.
interstitial cell of Cajal link
receptor signaling protein tyrosine kinase activity link ↑ INCREASED signal transduction link ↑ INCREASED
gastrointestinal tract link
Downstream
RAS-MAPK Pathway Activation KIT phosphorylation activates RAS-RAF-MEK-ERK cascade
PI3K-AKT Pathway Activation KIT phosphorylation recruits PI3K leading to AKT activation
Show evidence (1 reference)
PMID:12181401 SUPPORT
"Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors."
This landmark NEJM study established that constitutive KIT activation is the critical driver of GIST pathogenesis.
PDGFRA Receptor Activation
PDGFRA mutations, particularly D842V in the activation loop, result in constitutive kinase activity. These mutations activate similar downstream pathways as KIT but show different drug sensitivity profiles.
platelet-derived growth factor receptor signaling pathway link ↑ INCREASED
Downstream
RAS-MAPK Pathway Activation PDGFRA phosphorylation activates RAS-RAF-MEK-ERK cascade
PI3K-AKT Pathway Activation PDGFRA phosphorylation recruits PI3K leading to AKT activation
RAS-MAPK Pathway Activation
Constitutive KIT or PDGFRA activation drives the RAS-RAF-MEK-ERK signaling cascade, promoting cell proliferation. This pathway represents a potential therapeutic target when primary resistance to KIT/PDGFRA inhibitors occurs.
MAPK cascade link ↑ INCREASED
PI3K-AKT Pathway Activation
Constitutive KIT or PDGFRA activation recruits PI3K and activates the PI3K-AKT-mTOR signaling cascade, promoting cell survival and resistance to apoptosis. This pathway cooperates with MAPK signaling to drive tumorigenesis.
phosphatidylinositol 3-kinase signaling link ↑ INCREASED
✶

Histopathology

1
Mesenchymal Tumor VERY_FREQUENT
Gastrointestinal stromal tumor is the most common mesenchymal tumor of the GI tract.
Show evidence (1 reference)
PMID:22937603 SUPPORT
"Gastrointestinal stromal tumor, i.e., GIST is by far the most common mesenchymal"
Abstract identifies GIST as the most common mesenchymal tumor of the GI tract.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Gastrointestinal Stromal Tumor Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Blood 1
Gastrointestinal Bleeding FREQUENT Gastrointestinal hemorrhage (HP:0002239)
Digestive 1
Bowel Obstruction OCCASIONAL Intestinal obstruction (HP:0005214)
Constitutional 2
Abdominal Mass VERY_FREQUENT Abdominal pain (HP:0002027)
Fatigue FREQUENT Fatigue (HP:0012378)
Growth 1
Weight Loss OCCASIONAL Weight loss (HP:0001824)
🧬

Genetic Associations

2
KIT (Somatic Activating Mutations)
Show evidence (1 reference)
CGGV:assertion_fa076c63-8ffe-46ff-ba44-255a6fca07e5-2020-01-14T184619.396Z SUPPORT Other
"KIT | HGNC:6342 | gastrointestinal stromal tumor | MONDO:0011719 | AD | Definitive"
ClinGen classifies the KIT-gastrointestinal stromal tumor gene-disease relationship as definitive with autosomal dominant inheritance.
PDGFRA (Somatic Activating Mutations)
Show evidence (1 reference)
CGGV:assertion_08bbf13f-bc04-47a7-a3c5-1ec6abfc9190-2020-01-13T195509.878Z SUPPORT Other
"PDGFRA | HGNC:8803 | gastrointestinal stromal tumor | MONDO:0011719 | AD | Definitive"
ClinGen classifies the PDGFRA-gastrointestinal stromal tumor gene-disease relationship as definitive with autosomal dominant inheritance.
💊

Treatments

4
Imatinib
Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352
Agent: imatinib ↗
First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.
Show evidence (1 reference)
PMID:12181401 SUPPORT
"Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist..."
The Demetri et al. NEJM study demonstrated that imatinib achieves objective responses in 53.7% of advanced GIST patients by inhibiting the KIT signaling pathway.
Sunitinib
Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352
Agent: sunitinib ↗
Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.
Avapritinib
Action: pharmacotherapy MAXO:0000058
Agent: avapritinib ↗
Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V mutations and KIT exon 17 mutations. First agent to show efficacy in D842V mutant GIST, which is resistant to imatinib.
Surgical Resection
Action: surgical procedure MAXO:0000004
Primary treatment for localized GIST. Complete resection with negative margins is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate organ-preserving surgery.
🔬

Biochemical Markers

2
KIT (CD117) Immunohistochemistry
Molecular Genotyping
{ }

Source YAML

click to show 
name: Gastrointestinal Stromal Tumor
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-04-22T20:13:21Z'
description: >-
  Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of
  the gastrointestinal tract, arising from the interstitial cells of Cajal or their
  precursors. GISTs are characterized by activating mutations in KIT (85%) or PDGFRA
  (10%) receptor tyrosine kinases, which drive constitutive kinase activation and
  tumor growth. The identification of these driver mutations revolutionized treatment,
  with imatinib demonstrating dramatic responses and establishing GIST as a paradigm
  for targeted therapy in solid tumors.
categories:
- Gastrointestinal Cancer
- Sarcoma
- Mesenchymal Neoplasm
parents:
- gastrointestinal neoplasm
has_subtypes:
- name: KIT-mutant GIST
  description: >-
    Approximately 85% of GISTs harbor activating mutations in KIT, most commonly
    in exon 11 (juxtamembrane domain) but also in exons 9, 13, and 17. Different
    mutations confer variable sensitivity to tyrosine kinase inhibitors.
- name: PDGFRA-mutant GIST
  description: >-
    Approximately 10% of GISTs harbor PDGFRA mutations, typically exon 18 D842V
    which is resistant to imatinib. These tumors often arise in the stomach and
    have an epithelioid morphology.
- name: Wild-type GIST
  description: >-
    Approximately 10-15% of GISTs lack KIT or PDGFRA mutations. This group includes
    SDH-deficient GISTs (pediatric/young adult), NF1-associated GISTs, and GISTs
    with BRAF, RAS, or receptor tyrosine kinase fusions.
pathophysiology:
- name: KIT Receptor Tyrosine Kinase Activation
  description: >-
    Gain-of-function mutations in KIT result in constitutive receptor dimerization
    and kinase activation without ligand (stem cell factor) binding. This drives
    downstream signaling through RAS-MAPK and PI3K-AKT pathways, promoting cell
    proliferation and survival.
  cell_types:
  - preferred_term: interstitial cell of Cajal
    term:
      id: CL:0002088
      label: interstitial cell of Cajal
  biological_processes:
  - preferred_term: receptor signaling protein tyrosine kinase activity
    modifier: INCREASED
    term:
      id: GO:0006468
      label: protein phosphorylation
  - preferred_term: signal transduction
    modifier: INCREASED
    term:
      id: GO:0007165
      label: signal transduction
  gene_products:
  - preferred_term: KIT receptor
    term:
      id: NCIT:C17328
      label: Mast/Stem Cell Growth Factor Receptor Kit
  locations:
  - preferred_term: gastrointestinal tract
    term:
      id: UBERON:0005409
      label: alimentary part of gastrointestinal system
  downstream:
  - target: RAS-MAPK Pathway Activation
    description: KIT phosphorylation activates RAS-RAF-MEK-ERK cascade
  - target: PI3K-AKT Pathway Activation
    description: KIT phosphorylation recruits PI3K leading to AKT activation
  evidence:
  - reference: PMID:12181401
    reference_title: "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors."
    supports: SUPPORT
    snippet: "Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors."
    explanation: This landmark NEJM study established that constitutive KIT activation is the critical driver of GIST pathogenesis.
- name: PDGFRA Receptor Activation
  description: >-
    PDGFRA mutations, particularly D842V in the activation loop, result in
    constitutive kinase activity. These mutations activate similar downstream
    pathways as KIT but show different drug sensitivity profiles.
  biological_processes:
  - preferred_term: platelet-derived growth factor receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0048008
      label: platelet-derived growth factor receptor signaling pathway
  downstream:
  - target: RAS-MAPK Pathway Activation
    description: PDGFRA phosphorylation activates RAS-RAF-MEK-ERK cascade
  - target: PI3K-AKT Pathway Activation
    description: PDGFRA phosphorylation recruits PI3K leading to AKT activation
- name: RAS-MAPK Pathway Activation
  description: >-
    Constitutive KIT or PDGFRA activation drives the RAS-RAF-MEK-ERK signaling
    cascade, promoting cell proliferation. This pathway represents a potential
    therapeutic target when primary resistance to KIT/PDGFRA inhibitors occurs.
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
- name: PI3K-AKT Pathway Activation
  description: >-
    Constitutive KIT or PDGFRA activation recruits PI3K and activates the
    PI3K-AKT-mTOR signaling cascade, promoting cell survival and resistance
    to apoptosis. This pathway cooperates with MAPK signaling to drive tumorigenesis.
  biological_processes:
  - preferred_term: phosphatidylinositol 3-kinase signaling
    modifier: INCREASED
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
histopathology:
- name: Mesenchymal Tumor
  finding_term:
    preferred_term: Gastrointestinal Stromal Tumor
    term:
      id: NCIT:C3868
      label: Gastrointestinal Stromal Tumor
  frequency: VERY_FREQUENT
  description: Gastrointestinal stromal tumor is the most common mesenchymal tumor of the GI tract.
  evidence:
  - reference: PMID:22937603
    reference_title: "[Gastrointestinal stromal tumor]."
    supports: SUPPORT
    snippet: "Gastrointestinal stromal tumor, i.e., GIST is by far the most common mesenchymal"
    explanation: Abstract identifies GIST as the most common mesenchymal tumor of the GI tract.

phenotypes:
- category: Gastrointestinal
  name: Abdominal Mass
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    A palpable abdominal mass is often the presenting sign, particularly with
    larger tumors. GISTs can range from small incidental findings to massive tumors.
  phenotype_term:
    preferred_term: Abdominal mass
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Gastrointestinal
  name: Gastrointestinal Bleeding
  frequency: FREQUENT
  description: >-
    GI bleeding may present as hematemesis, melena, or chronic occult blood loss
    leading to iron deficiency anemia. Bleeding occurs when tumors ulcerate into
    the GI lumen.
  phenotype_term:
    preferred_term: Gastrointestinal hemorrhage
    term:
      id: HP:0002239
      label: Gastrointestinal hemorrhage
- category: Gastrointestinal
  name: Bowel Obstruction
  frequency: OCCASIONAL
  description: >-
    Large tumors may cause partial or complete intestinal obstruction, particularly
    in the small bowel.
  phenotype_term:
    preferred_term: Intestinal obstruction
    term:
      id: HP:0005214
      label: Intestinal obstruction
- category: Constitutional
  name: Fatigue
  frequency: FREQUENT
  description: >-
    Fatigue may result from chronic blood loss and anemia or from advanced disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Constitutional
  name: Weight Loss
  frequency: OCCASIONAL
  description: >-
    Unintentional weight loss may occur with advanced or metastatic disease.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
biochemical:
- name: KIT (CD117) Immunohistochemistry
  biomarker_term:
    preferred_term: KIT protein
    term:
      id: NCIT:C17328
      label: Mast/Stem Cell Growth Factor Receptor Kit
  notes: >-
    Approximately 95% of GISTs are positive for KIT (CD117) by immunohistochemistry,
    making this the primary diagnostic marker. DOG1 (Discovered on GIST-1) is another
    sensitive and specific marker.
- name: Molecular Genotyping
  notes: >-
    Mutational analysis of KIT exons 9, 11, 13, 17 and PDGFRA exon 18 is essential
    for predicting TKI response. Secondary resistance mutations should be assessed
    at progression.
genetic:
- name: KIT
  association: Somatic Activating Mutations
  evidence:
  - reference: CGGV:assertion_fa076c63-8ffe-46ff-ba44-255a6fca07e5-2020-01-14T184619.396Z
    reference_title: "KIT / gastrointestinal stromal tumor (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "KIT | HGNC:6342 | gastrointestinal stromal tumor | MONDO:0011719 | AD | Definitive"
    explanation: ClinGen classifies the KIT-gastrointestinal stromal tumor gene-disease relationship as definitive with autosomal dominant inheritance.
  notes: >-
    KIT mutations occur in approximately 85% of GISTs. Exon 11 mutations (juxtamembrane
    domain) are most common and predict good imatinib response. Exon 9 mutations
    require higher imatinib doses. Exon 13/17 mutations are less common.
- name: PDGFRA
  association: Somatic Activating Mutations
  evidence:
  - reference: CGGV:assertion_08bbf13f-bc04-47a7-a3c5-1ec6abfc9190-2020-01-13T195509.878Z
    reference_title: "PDGFRA / gastrointestinal stromal tumor (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PDGFRA | HGNC:8803 | gastrointestinal stromal tumor | MONDO:0011719 | AD | Definitive"
    explanation: ClinGen classifies the PDGFRA-gastrointestinal stromal tumor gene-disease relationship as definitive with autosomal dominant inheritance.
  notes: >-
    PDGFRA mutations occur in approximately 10% of GISTs. The D842V mutation in
    exon 18 is most common and confers primary resistance to imatinib but responds
    to avapritinib.
treatments:
- name: Imatinib
  description: >-
    First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA
    kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg.
    Dramatically transformed outcomes for advanced GIST patients.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: imatinib
      term:
        id: CHEBI:45783
        label: imatinib
  evidence:
  - reference: PMID:12181401
    reference_title: "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors."
    supports: SUPPORT
    snippet: "Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy."
    explanation: The Demetri et al. NEJM study demonstrated that imatinib achieves objective responses in 53.7% of advanced GIST patients by inhibiting the KIT signaling pathway.
- name: Sunitinib
  description: >-
    Second-line treatment after imatinib failure or intolerance. Multi-kinase
    inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant
    secondary mutations.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: sunitinib
      term:
        id: CHEBI:38940
        label: sunitinib
- name: Avapritinib
  description: >-
    Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V
    mutations and KIT exon 17 mutations. First agent to show efficacy in D842V
    mutant GIST, which is resistant to imatinib.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: avapritinib
      term:
        id: NCIT:C123827
        label: Avapritinib
- name: Surgical Resection
  description: >-
    Primary treatment for localized GIST. Complete resection with negative margins
    is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate
    organ-preserving surgery.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
disease_term:
  preferred_term: gastrointestinal stromal tumor
  term:
    id: MONDO:0011719
    label: gastrointestinal stromal tumor

classifications:
  icdo_morphology:
    classification_value: Sarcoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
references:
- reference: DOI:10.1186/s12964-023-01411-x
  title: 'KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST'
  findings: []
- reference: DOI:10.3390/cancers15051498
  title: Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision
  findings: []
- reference: DOI:10.3390/cancers15072074
  title: 'Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives'
  findings: []
- reference: DOI:10.5935/2526-8732.20240468
  title: 'Gastrointestinal stromal tumors: advances in molecular characterization and therapeutic implications'
  findings: []
- reference: DOI:10.7759/cureus.101180
  title: 'Gastrointestinal Stromal Tumors: Histopathological Spectrum, Molecular Subtypes, and Implications for Targeted Therapy'
  findings: []
📚

References & Deep Research

References

5
DOI:10.1186/s12964-023-01411-x
KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST
No top-level findings curated for this source.
DOI:10.3390/cancers15051498
Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision
No top-level findings curated for this source.
DOI:10.3390/cancers15072074
Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
No top-level findings curated for this source.
DOI:10.5935/2526-8732.20240468
Gastrointestinal stromal tumors: advances in molecular characterization and therapeutic implications
No top-level findings curated for this source.
DOI:10.7759/cureus.101180
Gastrointestinal Stromal Tumors: Histopathological Spectrum, Molecular Subtypes, and Implications for Targeted Therapy
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Gastrointestinal Stromal Tumor
  • Category:
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 8

Key Pathophysiology Nodes

  • KIT Receptor Tyrosine Kinase Activation
  • PDGFRA Receptor Activation
  • RAS-MAPK Pathway Activation
  • PI3K-AKT Pathway Activation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1186/s12964-023-01411-x
  • DOI:10.3390/cancers15051498
  • DOI:10.3390/cancers15072074
  • DOI:10.5935/2526-8732.20240468
  • DOI:10.7759/cureus.101180
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 21 citations 2026-01-24T18:43:51.521581

Disease Pathophysiology Research Report

Target Disease - Disease Name: Gastrointestinal Stromal Tumor (GIST) - MONDO ID: not specified in available sources - Category: Mesenchymal tumor of the gastrointestinal tract

Pathophysiology description GISTs are mesenchymal neoplasms arising from or sharing lineage with interstitial cells of Cajal (ICC), the GI pacemaker cells that physiologically express KIT and orchestrate peristaltic signaling ("GISTs mostly derive from Cajal cell precursors"), explaining the near-universal diagnostic utility of KIT (CD117) and DOG1 immunostaining (publication date: 27 Feb 2023) (unk2023molecularmechanismsof pages 1-2). Constitutive activation of receptor tyrosine kinases (RTKs)—most commonly KIT and less often PDGFRA—drives ligand‑independent signaling through MAPK and PI3K/AKT cascades to promote proliferation, survival, and tumor progression (publication date: 27 Feb 2023; 30 Mar 2023) (unk2023molecularmechanismsof pages 1-2, catalano2023moleculartailoredtherapeutic pages 1-2). SDH-deficient GIST represents a distinct metabolic/epigenetic class characterized by loss of succinate dehydrogenase activity, oncometabolite (succinate) accumulation, and genome‑wide hypermethylation that alters transcriptional programs and hypoxia signaling; this subtype is typically KIT/PDGFRA-wild type and shows reduced sensitivity to classical KIT-directed TKIs (publication dates: Feb 2024; May 2024) (zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13). Rarer drivers include NF1 loss (RAS pathway hyperactivation), BRAF V600E, and fusions affecting NTRK or FGFR1, which converge on MAPK/PI3K networks and confer sensitivity to pathway- or fusion-directed agents in select cases (publication dates: 27 Feb 2023; May 2024) (unk2023molecularmechanismsof pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13).

Direct quotes supporting key statements - “Gastrointestinal stromal tumors (GISTs) are soft tissue sarcomas that mostly derive from Cajal cell precursors… identified using characteristic immunohistochemical staining for CD117 and DOG1.” (27 Feb 2023; URL: https://doi.org/10.3390/cancers15051498) (unk2023molecularmechanismsof pages 1-2) - “Gain-of-function mutations in KIT or PDGFRA genes represent the driving mutations in more than 90% of all GISTs.” (27 Feb 2023; URL: https://doi.org/10.3390/cancers15051498) (unk2023molecularmechanismsof pages 1-2) - “SDH-deficient GISTs… [show] metabolic consequences with oncometabolite succinate accumulation and epigenetic reprogramming.” (Feb 2024; URL: https://doi.org/10.1186/s12964-023-01411-x) (zhou2024kitmutationsand pages 16-17) - “Advances in DNA and RNA sequencing… revealed novel, potentially actionable drivers… including… NTRK3 (ETV6‑NTRK3) or FGFR1 (FGFR1‑TACC1).” (May 2024; URL: https://doi.org/10.5935/2526-8732.20240468) (lima2024gastrointestinalstromaltumors pages 12-13)

1) Core Pathophysiology - Primary mechanisms: Constitutive RTK activation (KIT, PDGFRA) drives downstream MAPK and PI3K/AKT/mTOR signaling; SDH loss produces succinate accumulation that inhibits α‑ketoglutarate–dependent dioxygenases (e.g., KDMs/TETs), causing global DNA/histone hypermethylation and pseudohypoxia programs; RAS pathway activation appears in NF1- or BRAF‑driven tumors; rare NTRK/FGFR fusions act as oncogenic drivers converging on MAPK/PI3K (publication dates: 27 Feb 2023; Feb 2024; May 2024; 30 Mar 2023) (unk2023molecularmechanismsof pages 1-2, zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13, catalano2023moleculartailoredtherapeutic pages 1-2). - Dysregulated pathways: RTK signaling; MAPK cascade; PI3K/AKT/mTOR; epigenetic regulation in SDH-deficient GIST; possible Hippo/YAP‑TAZ activation in KIT‑independent states (publication dates: Feb 2024; 2024) (zhou2024kitmutationsand pages 16-17, pedone2024evaluationofgene pages 13-17). - Affected cellular processes: Cell-cycle progression and survival signaling downstream of KIT/PDGFRA; metabolic rewiring and epigenetic remodeling in SDH deficiency; lineage programs of ICC-like cells; potential TME-mediated immune suppression contributing to resistance (publication dates: 27 Feb 2023; Feb 2024; 2024) (unk2023molecularmechanismsof pages 1-2, zhou2024kitmutationsand pages 16-17, pedone2024evaluationofgene pages 13-17).

2) Key Molecular Players - Genes/Proteins (HGNC): KIT; PDGFRA; SDHA/SDHB/SDHC/SDHD; NF1; BRAF; NTRK1/2/3; FGFR1 (publication dates: 27 Feb 2023; May 2024; Feb 2024) (unk2023molecularmechanismsof pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13, zhou2024kitmutationsand pages 16-17). - Chemical Entities (CHEBI): Succinate (oncometabolite in SDH-deficient GIST) (Feb 2024; May 2024) (zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13). - Cell Types (CL): Interstitial cells of Cajal as the putative cell of origin; tumor/immune stromal constituents variably represented (27 Feb 2023) (unk2023molecularmechanismsof pages 1-2). - Anatomical Locations (UBERON): Stomach and small intestine are dominant primary sites; gastric GIST is enriched for PDGFRA and SDH-deficient tumors; small intestine shows a higher frequency of KIT exon 9 and NF1-associated cases (30 Mar 2023; May 2024) (catalano2023moleculartailoredtherapeutic pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13).

3) Biological Processes (GO annotation) - Positive regulation of MAPK cascade; RAS signaling; phosphatidylinositol 3‑kinase signaling; receptor tyrosine kinase signaling; cell cycle progression; metabolic process of TCA cycle; regulation of chromatin organization and DNA methylation (27 Feb 2023; Feb 2024; May 2024; 2024) (unk2023molecularmechanismsof pages 1-2, zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13, pedone2024evaluationofgene pages 13-17).

4) Cellular Components (GO/locations) - Plasma membrane (KIT/PDGFRA RTKs); cytosol and nucleus (MAPK/PI3K signal transduction and transcriptional responses); mitochondrion (SDH complex in inner mitochondrial membrane); extracellular space (ligands/growth factors); potential Golgi retention of KIT under certain resistance states (Feb 2024) (zhou2024kitmutationsand pages 16-17).

5) Disease Progression - Sequence of events: Initiating driver alteration (KIT/PDGFRA activation; SDH loss; or NF1/BRAF/fusion) → constitutive signaling or metabolic/epigenetic dysregulation → expansion of ICC‑lineage tumor cells → local growth and risk-stratified progression by size/mitoses/site → metastatic spread (commonly liver/peritoneum) → under TKI pressure, emergence of heterogeneous secondary resistance mutations (especially multiple subclones with secondary KIT mutations) and/or pathway reactivation or noncanonical RTK trafficking (publication dates: 27 Feb 2023; Feb 2024; 30 Mar 2023) (unk2023molecularmechanismsof pages 1-2, zhou2024kitmutationsand pages 16-17, catalano2023moleculartailoredtherapeutic pages 1-2). - Distinct stages/phases: Localized resectable disease; advanced/metastatic disease (systemic therapy required); resistance evolution under sequential TKIs (imatinib→sunitinib→regorafenib→ripretinib; avapritinib for PDGFRA D842V) (30 Mar 2023) (catalano2023moleculartailoredtherapeutic pages 1-2).

6) Phenotypic Manifestations (HPO-style) - Gastrointestinal bleeding, abdominal pain/mass, anemia, and obstruction correlate with tumor location/size; multifocal gastric tumors in SDH-deficient or syndromic contexts; early‑onset presentation in SDH-deficient and pediatric cases; indolent but metastatic potential in SDH-deficient subtype; immunohistochemical KIT (CD117) and DOG1 positivity as diagnostic phenotypes (publication dates: 27 Feb 2023; May 2024; 30 Mar 2023) (unk2023molecularmechanismsof pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13, catalano2023moleculartailoredtherapeutic pages 1-2).

Recent developments and latest research (2023–2024 priority) - KIT/PDGFRA and resistance biology: A 2024 mechanistic review synthesizes how KIT expression/trafficking, PI3K-driven KIT overexpression, and noncanonical maintenance (e.g., “Golgi retention”) sustain oncogenic signaling and contribute to imatinib resistance, underscoring the need for strategies that suppress MAPK/PI3K reactivation and address intracellular localization (publication date: 12 Feb 2024; URL: https://doi.org/10.1186/s12964-023-01411-x) (zhou2024kitmutationsand pages 16-17). - SDH-deficient GIST: 2024–2024 reviews highlight succinate-driven inhibition of 2‑OG–dependent dioxygenases and the resulting global hypermethylation as central to pathogenesis. Comprehensive profiling reveals frequent SDH subunit alterations and SDHC epimutations, and advocates broader germline/methylation testing in wild-type GISTs (publication dates: Feb 2024; May 2024; URLs: https://doi.org/10.1186/s12964-023-01411-x; https://doi.org/10.5935/2526-8732.20240468) (zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13). - Rare drivers and fusion biology: 2023–2024 reviews report NTRK (ETV6‑NTRK3) and FGFR1 (FGFR1‑TACC) fusions in triple‑negative GIST, with therapeutic implications for TRK/FGFR inhibition; emerging cases and panels now capture these events more routinely (publication dates: May 2024; 2024; URLs: https://doi.org/10.5935/2526-8732.20240468) (lima2024gastrointestinalstromaltumors pages 12-13, pedone2024evaluationofgene pages 13-17). - Therapy implications: 2023 and 2024 overviews reiterate mutation-tailored sequencing of TKIs (imatinib, sunitinib, regorafenib, ripretinib; avapritinib for PDGFRA D842V) and emphasize comprehensive genomic profiling in wild‑type GIST to detect NF1/BRAF/fusion drivers guiding non‑KIT therapy (publication dates: 30 Mar 2023; 27 Feb 2023; URLs: https://doi.org/10.3390/cancers15072074; https://doi.org/10.3390/cancers15051498) (catalano2023moleculartailoredtherapeutic pages 1-2, unk2023molecularmechanismsof pages 1-2).

Current applications and real-world implementations - Diagnostics: Standard IHC with KIT (CD117) and DOG1, with reflex next‑generation sequencing to define KIT/PDGFRA exon variants, detect SDH deficiency (including immunohistochemical SDHB loss and SDHC promoter methylation), and find alternative oncogenic drivers (publication dates: 30 Mar 2023; 27 Feb 2023; May 2024) (catalano2023moleculartailoredtherapeutic pages 1-2, unk2023molecularmechanismsof pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13). - Treatment: Mutation‑guided TKI selection (e.g., imatinib sensitivity for most KIT exon 11/9; avapritinib for PDGFRA D842V; reduced TKI benefit in SDH‑deficient/NF1), and consideration of tumor‑agnostic TRK inhibitors when NTRK fusions are present (publication dates: 30 Mar 2023; May 2024) (catalano2023moleculartailoredtherapeutic pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13). - Surveillance and risk: Integration of anatomic site, size, and mitotic count in risk models, acknowledging distinct behaviors (e.g., gastric SDH-deficient patterns) (publication date: 30 Mar 2023) (catalano2023moleculartailoredtherapeutic pages 1-2).

Expert opinions and analysis (authoritative sources) - Reviews from 2023–2024 converge on a model wherein KIT/PDGFRA signaling and SDH‑loss epigenetics represent two principal and biologically divergent axes of GIST pathogenesis. These demand tailored diagnostics (IHC + exon‑level sequencing + SDH IHC/methylation + fusion detection) and tailored therapeutics (mutation‑specific TKIs vs. metabolic/epigenetic or pathway‑directed strategies), with emerging attention to resistance mechanisms beyond kinase mutations (e.g., altered trafficking, pathway rewiring) (publication dates: 27 Feb 2023; 12 Feb 2024; 30 Mar 2023) (unk2023molecularmechanismsof pages 1-2, zhou2024kitmutationsand pages 16-17, catalano2023moleculartailoredtherapeutic pages 1-2).

Relevant statistics and data from recent studies - Molecular frequency (approximate ranges summarized across recent reviews): KIT mutations ~75–80%, PDGFRA ~5–10%, wild‑type (including SDH‑deficient, NF1, BRAF, fusion‑positive) ~15%—with SDH deficiency a notable subset in wild‑type disease (publication dates: 30 Mar 2023; 27 Feb 2023; May 2024) (catalano2023moleculartailoredtherapeutic pages 1-2, unk2023molecularmechanismsof pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13). - Diagnostic performance: KIT (CD117) IHC positive in >95% of cases, while DOG1 adds sensitivity, particularly in KIT‑negative cases (publication date: 30 Mar 2023) (catalano2023moleculartailoredtherapeutic pages 1-2).

Ontology-structured annotations - Genes/Proteins (HGNC): KIT; PDGFRA; SDHA; SDHB; SDHC; SDHD; NF1; BRAF; NTRK1; NTRK2; NTRK3; FGFR1 (unk2023molecularmechanismsof pages 1-2, zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13, catalano2023moleculartailoredtherapeutic pages 1-2). - Biological Processes (GO): receptor tyrosine kinase signaling; MAPK cascade; phosphatidylinositol 3‑kinase signaling; cell cycle; tricarboxylic acid cycle; regulation of chromatin organization; DNA methylation (unk2023molecularmechanismsof pages 1-2, zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13, pedone2024evaluationofgene pages 13-17). - Cellular Components (GO): plasma membrane (KIT/PDGFRA); mitochondrion inner membrane (SDH complex); cytosol and nucleus (signal transduction/transcription); Golgi apparatus (noncanonical KIT trafficking in resistance) (zhou2024kitmutationsand pages 16-17, unk2023molecularmechanismsof pages 1-2). - Cell Types (CL): interstitial cells of Cajal; tumor-associated immune/stromal cells (concept) (unk2023molecularmechanismsof pages 1-2, pedone2024evaluationofgene pages 13-17). - Anatomical Locations (UBERON): stomach; small intestine (jejunum/ileum) (catalano2023moleculartailoredtherapeutic pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13). - Chemical Entities (CHEBI): succinate (zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13). - Phenotype associations (HPO examples): gastrointestinal bleeding; abdominal mass; anemia; early-onset neoplasm (SDH-deficient); multifocal gastric tumors (SDH-deficient/NF1 contexts) (unk2023molecularmechanismsof pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13).

Embedded summary artifact | Category | Item (ontology) | Mechanistic role in GIST | Subtype(s) | Key downstream / related pathways | Notes on therapeutic relevance | Evidence sources | |---|---|---|---|---|---|---| | Driver RTK | KIT (HGNC:KIT) | Constitutive activating RTK (gain-of-function mutations, often exon 11/9) driving proliferation/survival | KIT-mutant GIST (majority) | MAPK (RAS/RAF/MEK/ERK), PI3K/AKT/mTOR, JAK/STAT | Primary target of imatinib; secondary KIT mutations cause acquired resistance; guides TKI choice | (zhou2024kitmutationsand pages 16-17, catalano2023moleculartailoredtherapeutic pages 1-2) | | Driver RTK | PDGFRA (HGNC:PDGFRA) | Activating RTK mutations (e.g., exon 18 D842V) → ligand-independent signaling | PDGFRA-mutant GIST (subset) | MAPK, PI3K/AKT | PDGFRA D842V is primary imatinib‑resistant; avapritinib effective for D842V | (zhou2024kitmutationsand pages 16-17, catalano2023moleculartailoredtherapeutic pages 1-2) | | Metabolic tumor suppressor | SDHA/SDHB/SDHC/SDHD (SDH complex) | Loss of SDH → succinate accumulation (oncometabolite), metabolic rewiring and epigenetic hypermethylation | SDH-deficient GIST (KIT/PDGFRA‑WT) | TCA cycle disruption; inhibition of 2‑OG–dependent dioxygenases → altered chromatin/HIF signaling | Poor TKI sensitivity; rationale for metabolic/epigenetic therapeutic strategies | (pedone2024evaluationofgene pages 13-17, lima2024gastrointestinalstromaltumors pages 12-13, zhou2024kitmutationsand pages 16-17) | | RAS-pathway regulator | NF1 (HGNC:NF1) | Tumor suppressor loss → RAS pathway hyperactivation | NF1‑associated / wild‑type GIST (often multifocal, small intestine) | RAS/MAPK | Less benefit from imatinib; profiling can reveal alternate actionable nodes | (lima2024gastrointestinalstromaltumors pages 12-13, unk2023molecularmechanismsof pages 1-2) | | MAPK driver | BRAF (HGNC:BRAF) | Oncogenic mutations (e.g., V600E) activate MAPK signaling in a minority of cases | BRAF‑mutant GIST (rare) | MAPK | May respond to BRAF-targeted therapy in select cases | (pedone2024evaluationofgene pages 13-17, unk2023molecularmechanismsof pages 1-2) | | Fusion oncogenes | NTRK fusions (HGNC:NTRK1/2/3) | Fusion → constitutive TRK kinase activity activating proliferation/survival programs | Triple‑WT / fusion‑positive GISTs (rare) | MAPK, PI3K, PLCγ | Tumor‑agnostic TRK inhibitors (larotrectinib/entrectinib) are effective when present | (pedone2024evaluationofgene pages 13-17, lima2024gastrointestinalstromaltumors pages 12-13) | | Fusion oncogenes | FGFR1 fusions (HGNC:FGFR1) | Constitutive FGFR signaling via fusions/amplification | WT/fusion GIST subsets (rare) | MAPK, PI3K/AKT, PLCγ | FGFR inhibitors considered experimentally; potential mechanism of imatinib resistance via bypass signaling | (lima2024gastrointestinalstromaltumors pages 12-13, pedone2024evaluationofgene pages 13-17) | | Core signaling | PI3K/AKT pathway (GO) | Mediates survival, metabolism and growth downstream of RTKs | Across KIT/PDGFRA and some WT GISTs | PI3K → AKT → mTOR | Targetable with PI3K/mTOR axis inhibitors in trials/combination strategies | (zhou2024kitmutationsand pages 16-17, catalano2023moleculartailoredtherapeutic pages 1-2) | | Core signaling | MAPK pathway (GO:MAPK cascade) | Drives proliferation and transcriptional programs downstream of RTKs/RAS | Across multiple molecular subtypes | RAS → RAF → MEK → ERK | MAPK pathway reactivation contributes to resistance; MAPK-targeting strategies under investigation | (zhou2024kitmutationsand pages 16-17, unk2023molecularmechanismsof pages 1-2) | | Transcriptional regulator | Hippo / YAP‑TAZ (GO) | YAP/TAZ activation promotes KIT‑independent proliferation and drug resistance | Imatinib‑resistant / KIT‑independent tumors (models) | TEAD‑mediated transcription → CCND1, CTGF | Preclinical rationale for YAP inhibition to overcome KIT‑independence | (pedone2024evaluationofgene pages 13-17) | | Cell of origin | Interstitial cells of Cajal (CL:interstitial cells of Cajal) | Putative cell‑of‑origin with KIT expression and pacemaker physiology | Gastric and small intestinal GIST | KIT signaling axis | Explains lineage marker expression (KIT/DOG1) and tissue predilection | (unk2023molecularmechanismsof pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13) | | Tumor ecosystem | Tumor microenvironment / immune features (concept) | Immune cell composition (Tregs, IDO1+ DCs, TAMs), immunosuppressive interactions contribute to resistance and progression | Advanced / imatinib‑resistant GISTs show distinct immunosuppressive signatures | Immune checkpoints, TIGIT‑NECTIN2, BTLA‑TNFRSF14 axes | Limited ICI activity so far; TME profiling may enable combination immunotherapies | (zhou2024kitmutationsand pages 16-17, unk2023molecularmechanismsof pages 1-2) | | Anatomy | Stomach; small intestine / jejunum (UBERON:stomach; UBERON:small_intestine) | Primary anatomical sites with differing molecular spectra (gastric vs small bowel) | Gastric GIST (more PDGFRA/SDH), small intestine (more KIT exon9, NF1) | — | Site influences prognosis, risk stratification and surgical approach | (catalano2023moleculartailoredtherapeutic pages 1-2, lima2024gastrointestinalstromaltumors pages 12-13) | | Metabolite / oncometabolite | Succinate (CHEBI:succinate) | Accumulates with SDH loss → inhibits 2‑OG‑dependent dioxygenases → epigenetic reprogramming and HIF stabilization | SDH‑deficient GIST | TCA cycle disruption; epigenetic modifiers (KDMs) affected | Targets: epigenetic modulators, metabolic interventions (emerging) | (zhou2024kitmutationsand pages 16-17, lima2024gastrointestinalstromaltumors pages 12-13) | | Diagnostic marker | DOG1 (ANO1; HGNC:ANO1) | Sensitive IHC marker for GIST diagnosis independent of mutation | All histologic subtypes | — | Important diagnostic marker when KIT IHC/clinical context ambiguous | (catalano2023moleculartailoredtherapeutic pages 1-2) | | Diagnostic marker | CD117 (KIT) IHC marker | High sensitivity (>95%) reflecting KIT protein expression | All / KIT‑mutant and many WT GISTs | — | Standard diagnostic test; correlates with KIT pathway activity | (catalano2023moleculartailoredtherapeutic pages 1-2, unk2023molecularmechanismsof pages 1-2) | | Resistance mechanisms | PDGFRA D842V; secondary KIT mutations; noncanonical KIT trafficking (Golgi retention) | Primary resistance (D842V), acquired polyclonal secondary KIT mutations, and alternative KIT localization/trafficking sustaining signaling | Drives primary non‑response or later relapse across treated patients | Alters inhibitor binding or reactivates MAPK/PI3K | Therapeutic implications: avapritinib for D842V; sequential TKIs (sunitinib/regorafenib/ripretinib); need for combination/novel agents | (zhou2024kitmutationsand pages 16-17, catalano2023moleculartailoredtherapeutic pages 1-2, qasim2026gastrointestinalstromaltumors pages 1-2) |

Table: Compact table summarizing molecular, cellular, metabolic, diagnostic, and resistance anchors in GIST, with ontology tags and primary evidence references to inform mechanistic understanding and therapeutic decisions.

Evidence items (with URLs and publication dates) - Zhou et al., Cell Communication and Signaling. “KIT mutations and expression… overcoming IM resistance in GIST.” Published 12 Feb 2024. URL: https://doi.org/10.1186/s12964-023-01411-x (zhou2024kitmutationsand pages 16-17) - Unk et al., Cancers. “Molecular Mechanisms of GIST and Impact on Therapy.” Published 27 Feb 2023. URL: https://doi.org/10.3390/cancers15051498 (unk2023molecularmechanismsof pages 1-2) - Catalano et al., Cancers. “Molecular Tailored Therapeutic Options for GISTs.” Published 30 Mar 2023. URL: https://doi.org/10.3390/cancers15072074 (catalano2023moleculartailoredtherapeutic pages 1-2) - Lima et al., Brazilian Journal of Oncology. “Advances in molecular characterization and therapeutic implications.” Published May 2024. URL: https://doi.org/10.5935/2526-8732.20240468 (lima2024gastrointestinalstromaltumors pages 12-13) - Pedone et al., 2024. “Evaluation of gene expression and gene fusions in GIST” (publication venue/URL not specified in retrieved record) (pedone2024evaluationofgene pages 13-17) - Qasim et al., Cureus. “GIST: histopathological spectrum, molecular subtypes, targeted therapy.” Published Jan 2026. URL: https://doi.org/10.7759/cureus.101180 (qasim2026gastrointestinalstromaltumors pages 11-12, qasim2026gastrointestinalstromaltumors pages 2-3, qasim2026gastrointestinalstromaltumors pages 1-2)

Limitations Some items above cite narrative or regional reviews; direct primary datasets for certain statistics (e.g., exact subtype frequencies by site) were summarized from recent reviews rather than meta-analyses. Fusion prevalence remains low and heterogeneous across cohorts; detection depends on assay sensitivity (lima2024gastrointestinalstromaltumors pages 12-13, pedone2024evaluationofgene pages 13-17).

References

  1. (unk2023molecularmechanismsof pages 1-2): Mojca Unk, Barbara Jezeršek Novaković, and Srdjan Novaković. Molecular mechanisms of gastrointestinal stromal tumors and their impact on systemic therapy decision. Cancers, 15:1498, Feb 2023. URL: https://doi.org/10.3390/cancers15051498, doi:10.3390/cancers15051498. This article has 14 citations and is from a poor quality or predatory journal.

  2. (catalano2023moleculartailoredtherapeutic pages 1-2): Fabio Catalano, Malvina Cremante, Bruna Dalmasso, Chiara Pirrone, Agostina Lagodin D’Amato, Massimiliano Grassi, and Danila Comandini. Molecular tailored therapeutic options for advanced gastrointestinal stromal tumors (gists): current practice and future perspectives. Cancers, 15:2074, Mar 2023. URL: https://doi.org/10.3390/cancers15072074, doi:10.3390/cancers15072074. This article has 9 citations and is from a poor quality or predatory journal.

  3. (zhou2024kitmutationsand pages 16-17): Shishan Zhou, Omar Abdihamid, Fengbo Tan, Haiyan Zhou, Heli Liu, Zhi Li, Sheng Xiao, and Bin Li. Kit mutations and expression: current knowledge and new insights for overcoming im resistance in gist. Cell Communication and Signaling : CCS, Feb 2024. URL: https://doi.org/10.1186/s12964-023-01411-x, doi:10.1186/s12964-023-01411-x. This article has 48 citations.

  4. (lima2024gastrointestinalstromaltumors pages 12-13): Nildevande Firmino Lima, Marcello Moro Queiroz, Julia Sousa Leal Franco, Julia Sousa Lins, Eduardo Felício de Campos, Beatriz Mendes Awni, Luiz Guilherme Cernaglia Aureliano de Lima, Frederico Teixeira, Fábio de Oliveira Ferreira, Eduardo Hiroshi Akaishi, Fernanda Cunha Capareli, and Rodrigo Ramella Munhoz. Gastrointestinal stromal tumors: advances in molecular characterization and therapeutic implications. Brazilian Journal of Oncology, May 2024. URL: https://doi.org/10.5935/2526-8732.20240468, doi:10.5935/2526-8732.20240468. This article has 0 citations.

  5. (pedone2024evaluationofgene pages 13-17): E Pedone. Evaluation of gene expression profile and gene fusions in gastrointestinal stromal tumors: looking for novel predictive and prognostic biomarkers. Unknown journal, 2024.

  6. (qasim2026gastrointestinalstromaltumors pages 1-2): Hussein Qasim, Mohammad Abu Shugaer, Ahmad N Awawdeh, Tamara Dawaymeh, Karis Khattab, Musallam Al-oweiwi, Matteo Luigi Giuseppe Leoni, and Giustino Varrassi. Gastrointestinal stromal tumors: histopathological spectrum, molecular subtypes, and implications for targeted therapy. Cureus, Jan 2026. URL: https://doi.org/10.7759/cureus.101180, doi:10.7759/cureus.101180. This article has 0 citations and is from a poor quality or predatory journal.

  7. (qasim2026gastrointestinalstromaltumors pages 11-12): Hussein Qasim, Mohammad Abu Shugaer, Ahmad N Awawdeh, Tamara Dawaymeh, Karis Khattab, Musallam Al-oweiwi, Matteo Luigi Giuseppe Leoni, and Giustino Varrassi. Gastrointestinal stromal tumors: histopathological spectrum, molecular subtypes, and implications for targeted therapy. Cureus, Jan 2026. URL: https://doi.org/10.7759/cureus.101180, doi:10.7759/cureus.101180. This article has 0 citations and is from a poor quality or predatory journal.

  8. (qasim2026gastrointestinalstromaltumors pages 2-3): Hussein Qasim, Mohammad Abu Shugaer, Ahmad N Awawdeh, Tamara Dawaymeh, Karis Khattab, Musallam Al-oweiwi, Matteo Luigi Giuseppe Leoni, and Giustino Varrassi. Gastrointestinal stromal tumors: histopathological spectrum, molecular subtypes, and implications for targeted therapy. Cureus, Jan 2026. URL: https://doi.org/10.7759/cureus.101180, doi:10.7759/cureus.101180. This article has 0 citations and is from a poor quality or predatory journal.